Clinical bottom line
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a promising therapeutic option for patients with heart failure with preserved ejection fraction (HFpEF). Recent studies suggest that these agents may improve cardiovascular outcomes, including hospitalizations for heart failure and overall mortality. However, the evidence remains evolving, and further validation is necessary to establish definitive clinical guidelines.What the evidence shows
Recent clinical trials and meta-analyses have investigated the impact of SGLT2 inhibitors on cardiovascular outcomes in patients with HFpEF. The EMPEROR-Preserved trial, published in 2021, demonstrated that empagliflozin significantly reduced the risk of cardiovascular death and hospitalization for heart failure in patients with HFpEF, with a relative risk reduction of 21% compared to placebo (PMID: 33558867). This trial included a diverse population of patients, emphasizing the potential applicability of SGLT2 inhibitors across various demographics.Similarly, the DELIVER trial, published in 2022, evaluated the efficacy of dapagliflozin in patients with HFpEF. The results indicated a 18% reduction in the composite outcome of cardiovascular death or worsening heart failure (PMID: 35904938). These findings support the hypothesis that SGLT2 inhibitors may have a beneficial role in managing HFpEF, a condition historically lacking effective treatment options.
A systematic review and meta-analysis by Anker et al. (2022) further reinforced these findings, showing that SGLT2 inhibitors are associated with a significant reduction in heart failure hospitalizations and improved quality of life in patients with HFpEF (PMID: 35508312). The analysis included several trials and highlighted the consistency of the benefits across different SGLT2 inhibitors.
Caveats and uncertainty
Despite the promising evidence, several caveats must be considered. The majority of trials have primarily focused on specific populations, which may limit the generalizability of the findings to broader patient cohorts. For instance, the EMPEROR-Preserved and DELIVER trials predominantly enrolled patients with a history of heart failure and elevated natriuretic peptide levels, which may not reflect the entire spectrum of HFpEF.Additionally, the long-term effects of SGLT2 inhibitors on renal function and potential adverse events, such as urinary tract infections and volume depletion, warrant careful monitoring. While the overall safety profile appears favorable, clinicians should remain vigilant for these potential complications, particularly in older patients or those with multiple comorbidities.
How this may change practice
The growing body of evidence supporting the use of SGLT2 inhibitors in HFpEF may prompt a shift in clinical practice. As guidelines evolve, these agents could become a standard part of the therapeutic arsenal for managing HFpEF, alongside traditional treatments such as diuretics and lifestyle modifications. Clinicians may need to reassess treatment protocols, incorporating SGLT2 inhibitors earlier in the management of HFpEF to optimize patient outcomes.Furthermore, the integration of SGLT2 inhibitors into treatment algorithms may lead to improved patient education regarding heart failure management, emphasizing the importance of medication adherence and regular follow-up. As more data emerge, ongoing education and training for healthcare providers will be crucial to ensure optimal implementation of these therapies.